Search

Compugen Ltd

Cerrado

2.09 -0.95

Resumen

Variación precio

24h

Actual

Mínimo

2.02

Máximo

2.11

Métricas clave

By Trading Economics

Ingresos

663K

-7M

Ventas

426K

2.6M

P/B

Media del Sector

5.632

68.089

BPA

-0.06

Margen de beneficios

-269.254

Empleados

75

EBITDA

665K

-7M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 Meses

+112.26% upside

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

-22M

203M

Apertura anterior

3.04

Cierre anterior

2.09

Compugen Ltd Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

13 nov 2026, 23:56 UTC

Cheniere Energy, Inc. is trading higher in after-market hours, despite a slight decline from earlier gains, remaining above its 20-day moving average.

13 nov 2026, 23:56 UTC

Dell Technologies Inc is experiencing a notable decline in after-market trading, continuing a trend of lower daily closes observed over recent sessions.

13 nov 2026, 23:56 UTC

Kraft Heinz Company traded higher in after-market hours, maintaining a position above its 20-day moving average and closing up for the third consecutive session.

13 nov 2026, 23:55 UTC

Molson Coors Beverage Company shares are trading modestly lower in after-market hours, reflecting a lack of recovery from earlier losses since Friday's close.

13 nov 2026, 23:52 UTC

China's October 2026 House Price Index release set for November 16 amid ongoing price declines and global economic pressures.

13 nov 2026, 23:52 UTC

Australia's Full Time Employment Change report on November 19, 2026, may reflect cautious market sentiment amid steady inflation and mixed job quality indicators.

13 nov 2026, 23:52 UTC

Australia's upcoming employment change data on November 19, 2026, faces scrutiny amid recent job losses and concerns over labor quality and wage growth.

13 nov 2026, 23:52 UTC

UK Consumer Confidence Set for Release Amidst Economic Anxiety and Inflation Concerns

13 nov 2026, 23:52 UTC

Australia's unemployment rate for October 2026 set to release on November 19 amid rising inflation and cautious economic sentiment, with September figures at a surprising high of 4.7%.

13 nov 2026, 23:52 UTC

Market Anticipates Fed Vice Chair Jefferson's Speech on November 14 Amid Rising Inflation Concerns and Potential Rate Hikes.

13 nov 2026, 23:51 UTC

Rockwell Automation Inc is declining in after-market trading, following broader market losses and concerns over Nvidia's CEO resignation impacting the AI sector.

13 nov 2026, 23:51 UTC

ONEOK Inc shares advanced modestly in after-market trading on Friday, marking six consecutive higher daily closes.

13 nov 2026, 23:51 UTC

Correlated Moves

Keysight Technologies is trading lower in after-hours activity, influenced by Nvidia's CEO resignation and broader weakness in the semiconductor sector.

13 nov 2026, 23:51 UTC

Cloudflare, Inc. is declining in after-market trading, influenced by broader market sell-offs in technology stocks amid concerns over the AI sector and rising Treasury yields.

13 nov 2026, 23:51 UTC

Correlated Moves

NETSTREIT Corp. is trading lower in after-market hours, continuing a decline since Friday's close, in line with the movement of the Direxion Daily Real Estate Bull 3X ETF.

13 nov 2026, 23:51 UTC

Correlated Moves

NNN REIT, Inc. is trading lower in after-hours activity, influenced by a decline in the Direxion Daily Real Estate Bull 3X ETF.

13 nov 2026, 23:51 UTC

HCI Group Inc has advanced in after-market trading, recovering from earlier losses and reflecting a notable upward move since Friday's close.

13 nov 2026, 23:51 UTC

News
Correlated Moves

MaxLinear, Inc. shares are declining in after-market hours, influenced by Nvidia's CEO resignation and broader market sell-off amid rising Treasury yields.

13 nov 2026, 23:51 UTC

Palantir Technologies Inc. is moving lower in after-market hours, tracking a broader market decline amid concerns over Nvidia's CEO resignation and rising Treasury yields.

13 nov 2026, 23:51 UTC

Correlated Moves
Event

Construction Partners, Inc. will report Q4 FY2026 earnings on November 19, 2026, with an EPS estimate of $1.07 and revenue of $1.1 billion.

13 nov 2026, 23:51 UTC

Avis Budget Group Inc shares are trading higher in after-hours, showing increased volatility and remaining significantly above its 20-day moving average.

13 nov 2026, 23:51 UTC

Correlated Moves

EMCOR Group, Inc. shares are lower in after-market trading, following declines linked to Nvidia's CEO resignation and rising Treasury yields impacting technology stocks.

13 nov 2026, 23:51 UTC

Hingham Institution for Savings shares are moving lower in after-market trading, following a broader market decline and ongoing concerns in the AI sector.

13 nov 2026, 23:51 UTC

Trip.com Group Ltd is experiencing a modest decline in after-market trading, reaching its lowest point since Friday's close.

13 nov 2026, 23:51 UTC

Correlated Moves

Applied Materials Inc is lower in after-market trading, reflecting broader market declines amid concerns over Nvidia's CEO resignation and rising Treasury yields.

13 nov 2026, 23:51 UTC

News

Interactive Brokers Group Inc is trading lower in after-market hours, impacted by concerns over Nvidia's CEO resignation and rising Treasury yields.

13 nov 2026, 23:46 UTC

VeriSign, Inc. shares traded roughly flat in after-market hours following a slight decline from Friday's close, remaining above its 20-day moving average.

13 nov 2026, 23:46 UTC

Teradata Corporation's shares traded modestly lower during after-market hours.

13 nov 2026, 23:46 UTC

Check Point Software Technologies Ltd. is trading higher in after-market hours, showing notable strength from a low point shortly after the market closed.

13 nov 2026, 23:46 UTC

BlackRock, Inc. traded roughly flat in after-market hours, remaining above its 20-day moving average and near the upper end of its one-month trading range.

Comparación entre iguales

Cambio de precio

Compugen Ltd previsión

Precio Objetivo

By TipRanks

112.26% repunte

Estimación a 12 Meses

Media 4.5 USD  112.26%

Máximo 6 USD

Mínimo 4 USD

De acuerdo con 4 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Compugen Ltd Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

4 ratings

4

Comprar

0

Mantener

0

Vender

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Compugen Ltd

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.
help-icon Live chat